Drugs for Neglected Diseases initiative - DNDi

Survive and thrive: Improving the global AMR response for healthier children and newborns.  Antimicrobial resistance (AMR) poses a significant threat to children's survival and health worldwide, with 1 out of every 5 deaths due to AMR occurring in children under the age of five.  Even though children are disproportionately affected by drug-resistant infections, they are being left behind in the current global AMR response.  GARDP's paediatric policy paper examines the reasons for this situation and provides recommendations to put children at the centre of our AMR response.  “Newborns in many African countries are disproportionately affected by drug-resistant infections. We hope GARDP’s work will ultimately lead to a better outcome for newborns so that they are able to survive and thrive.” Professor Ntobeko Ntusi – President and CEO of the South African Medical Research Council, which supports GARDP’s neonatal sepsis programme Learn more: https://lnkd.in/dc7w_yBM #AMR #PolicyPaper #AntibioticResistance #ChildrenHealth #SurviveAndThrive 

🌟Breaking down science for everyone: insights into fungal mycetoma treatment🌟 The Mycetoma Research Centre in Khartoum, Sudan, and DNDi conducted the first-ever randomized Phase II clinical trial on a new treatment for fungal mycetoma, a highly neglected tropical disease affecting people in rural areas. Our results published in The Lancet Group – now available in the print version this month – showed that the new oral treatment fosravuconazole is safe, patient-friendly, and effective in treating mycetoma. And since treatment is required for one year, the once-weekly dose of fosravuconazole is also easier for patients than the current standard treatment, which requires a twice-daily dose. 👉 To make these important findings accessible to all, we’ve developed a Science Explained summary—a simple, easy-to-understand overview of the study. ⤵ 📄 Read the Science Explained summary here: https://lnkd.in/e7E8VAWP For those who want to explore the full publication, find it here: https://lnkd.in/eJkw998T We thank our partners who made this clinical trial possible Mycetoma Research Centre, Erasmus MC, and Eisai Co., Ltd., and we aim to continue efforts to find a cure for this very neglected disease. #ScienceExplained #Mycetoma #NeglectedDiseases #GlobalHealth #AccessibleScience

We welcome the establishment of the G20 Coalition for Local and Regional Production, Innovation, and Equitable Access 👏 The Coalition was announced last week at the G20 Health Ministers’ Meeting in Rio de Janeiro, Brazil. 🌐About the Coalition ⤵   ✅It is designed to promote access to vaccines, therapeutics, diagnostics, and other health technologies, focussing primarily on neglected diseases and at-risk populations.  ✅It aims to facilitate better access to essential health technologies, especially in low- and middle-income countries.   ✅It is centred on voluntary cooperation, comprising G20 Member States, non-G20 countries, and international organizations.  ✅It seeks to promote synergies with existing and future initiatives, funding channels, and philanthropic organizations. 🔗 Read our statement on the Coalition here: https://lnkd.in/eFtaZBZX Our teams had the opportunity to participate in the 5th Meeting of the G20 Health Working Group and G20 Health Ministerial Meeting. ⤵ 🔸 At the High-Level Meeting on One Health, we stressed that   action is needed to address fungal diseases, which are worsening due to climate change, antifungal resistance, and limited access to treatments, especially for vulnerable populations in lower-income countries. 🔸 At the High-level Meeting on Climate Change, Health, and Equity, we welcomed the G20’s commitment to put equity at the core of climate and health initiatives and urged action towards developing and ensuring equitable access to vaccines, diagnostics, and medicines for climate-sensitive diseases. 🔸 At the Health Ministerial Meeting, we recommended that one pilot project of the G20 Coalition focus on developing new therapeutics for dengue, a neglected and climate-sensitive disease with no current treatments that affects many G20 countries.  🔗 Read our full interventions here: https://lnkd.in/eUpwN6sB #G20Brazil #OneHealth #ClimateChange #HealthEquity

The #G20 Health Ministerial Meeting just concluded with two major achievements:  👉 the adoption of the Declaration on Climate Change, Health, Equity, and One Health 👉 the establishment of the Global Coalition for Local Production and Innovation It was an honor to be part of this pivotal moment, and I look forward to the next steps and continued progress at the G20 discussions in South Africa next year! #G20Brazil #ClimateChange #HealthEquity #OneHealth

In a recent article by The Medicine Maker, Delali A., our North America Director, calls for a new R&D model that puts neglected communities first.   Current gaps in medical innovation: 🌍 Millions of people lack access to diagnostics, treatments, and vaccines, especially for neglected diseases. 👩👧 Women and children are disproportionately impacted by the lack of medical research and tailored treatments. 🌡️ Climate change is accelerating the spread of climate-sensitive diseases, like dengue, hitting hardest in communities already facing climate challenges.   What we need: A patient-centered R&D model that prioritizes community needs over profits.   At DNDi, we work alongside communities, doctors, and researchers in regions affected by neglected diseases. As Delali says, “If we realize a drug candidate or a new project won’t fit patients’ specific needs, we tweak it until it does – or we stop developing it.”   🔗 Read more on reshaping R&D for global health: https://lnkd.in/eD2J-PTv   #GlobalHealth #HealthcareEquity #BeatNTDs  

At DNDi, we're committed to advancing research on new treatments for neglected diseases. One way we do this is by conducting clinical studies around the world. But there’s another vital way we’re supporting progress: by sharing our study data with other researchers. 📊🤝   Our study data can help others to deliver life-saving treatments for neglected diseases, but we must protect the privacy of our study participants. Thanks to our partners Privacy Analytics, we’re achieving this by de-identifying datasets before sharing them, ensuring privacy while promoting transparency.   This #OpenAccessWeek, we’re excited to share a case study by Privacy Analytics on how we’re advancing global health research together. Learn more here: https://lnkd.in/eVm6GDFA   #OAWeek #NeglectedDiseases #GlobalHealth #Research

🚨 Where are the funds for diseases affecting one billion of the world's poorest? Neglected diseases continue to impact over one billion people, but the funding for prevention, treatment, and research and development (R&D) remains alarmingly insufficient. Thank you Salud por Derecho - Right to Health Foundation, Fundacion ANESVAD, Médicos Sin Fronteras España, AGENCIA ESPAÑOLA DE COOPERACION INTERNACIONAL PARA EL DESARROLLO - AECID, Pan American Health Organization for joining us at this important event. It was a timely opportunity to come together and discuss the challenges faced by R&D actors and potential solutions for addressing the severe underfunding of efforts to combat these diseases. 👉 Find out more by reading this article published in Planeta Futuro EL PAÍS: https://lnkd.in/gxmiS8ZJ #NTDs #GlobalHealth #NeglectedDiseases

Community over commercialization, the theme of open access week this year, resonates with our values at DNDi: we build partnerships to find cures for diseases that have no commercial interest. In the last few months, we have published about: 💊Testing a drug for the devasting fungal disease mycetoma, with partners in Sudan 🔬 Investigating how people with different forms of leishmaniasis respond to the same treatment, with partners in six countries in Europe and Africa 📜 A protocol to help researchers implement an important in vivo model of Chagas disease, with partners in Brazil and all of these publications are available open access! 🔗 Two dose levels of once-weekly fosravuconazole versus daily itraconazole in combination with surgery in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial. https://lnkd.in/exMj9C-Y 🔗 Disease-specific differences in pharmacokinetics of paromomycin and miltefosine between post-kala-azar dermal leishmaniasis and visceral leishmaniasis patients in eastern Africa. https://lnkd.in/erGWx4Gh 🔗 Demystifying In Vivo Bioluminescence Imaging of a Chagas Disease Mouse Model for Drug Efficacy Studies. https://lnkd.in/ey3BswGv #OAWeek #NTDs #partnerships

"I hate to see my face in the mirror. I don’t like to go to study or go to school." Munni is suffering from post-kala azar dermal leishmaniasis (PKDL), a painful skin condition caused by black fever, also known as visceral leishmaniasis (VL). Her lesions, resembling the disfigurements caused by leprosy, are a harsh reminder of the disease’s lingering impact. 🌍Climate change is worsening the spread of black fever, which causes weight loss, high fever, and organ damage in individuals like Munni. Rising temperatures and erratic rainfall help sandflies thrive, making the disease more widespread. 🔬Our South Asia director, Dr Kavita Singh, emphasises the urgent need for simplified treatments and faster diagnostics for VL. 🔗 https://lnkd.in/e_UasdEt Aliya Bashir The Xylom #ClimateChange #BlackFever

🌟We are honored to receive Research!America: Discovery. Innovation. Health.’s Rapid Translation Award for our contribution to public health progress in a timely way. Our North America Executive Director, Delali A., will accept the award on behalf of DNDi. At DNDi, we remain dedicated to accelerating drug development for neglected diseases, which primarily impact poor and marginalized communities. A big thank you to all our partners for their continued support! Together, we are making meaningful progress in global health. 🌍💊 #RAAwards #GlobalHealth #NeglectedDiseases #Innovation #Partnerships